426 related articles for article (PubMed ID: 1452928)
1. Flosequinan, a new vasodilator: systemic and coronary hemodynamics and neuroendocrine effects in congestive heart failure.
Cavero PG; De Marco T; Kwasman M; Lau D; Liu M; Chatterjee K
J Am Coll Cardiol; 1992 Dec; 20(7):1542-8. PubMed ID: 1452928
[TBL] [Abstract][Full Text] [Related]
2. Sustained hemodynamic response to flosequinan in patients with heart failure receiving angiotensin-converting enzyme inhibitors.
Gottlieb SS; Kukin ML; Penn J; Fisher ML; Cines M; Medina N; Yushak M; Taylor M; Packer M
J Am Coll Cardiol; 1993 Oct; 22(4):963-7. PubMed ID: 8409070
[TBL] [Abstract][Full Text] [Related]
3. Effects of low-dose flosequinan on left ventricular systolic and diastolic chamber performance.
Starling MR
Am Heart J; 1994 Jul; 128(1):124-33. PubMed ID: 8017265
[TBL] [Abstract][Full Text] [Related]
4. The effect of flosequinan in patients with acute-onset heart failure complicating acute myocardial infarction.
Schneeweiss A; Wynne RD; Marmor A
Jpn Heart J; 1989 Sep; 30(5):627-34. PubMed ID: 2614925
[TBL] [Abstract][Full Text] [Related]
5. Cumulative hemodynamic response to short-term treatment with flosequinan (BTS 49465), a new direct-acting vasodilator drug, in severe chronic congestive heart failure.
Kessler PD; Packer M; Medina N; Yushak M
J Cardiovasc Pharmacol; 1988 Jul; 12(1):6-11. PubMed ID: 2459536
[TBL] [Abstract][Full Text] [Related]
6. The central haemodynamic effects of a single intravenous dose of flosequinan in patients with severe heart failure.
Markus H; Cowley AJ
Eur J Clin Pharmacol; 1991; 40(6):535-8. PubMed ID: 1884731
[TBL] [Abstract][Full Text] [Related]
7. Long-term vasodilator treatment with flosequinan does not lead to hemodynamic tolerance or neurohormonal activation in severe heart failure.
Bartels GL; Remme WJ; Look MP; Kruijssen DA
J Card Fail; 1995 Mar; 1(2):117-25. PubMed ID: 9420641
[TBL] [Abstract][Full Text] [Related]
8. Haemodynamic and neurohumoral effects of flosequinan in severe heart failure: similarities and differences compared with intravenous nitroglycerin therapy.
Dakak N; Makhoul N; Merdler A; Yechiely H; Kahana L; Halon DA; Schneeweiss A; Lewis BS
Eur Heart J; 1993 Jun; 14(6):836-44. PubMed ID: 8325314
[TBL] [Abstract][Full Text] [Related]
9. Central and regional hemodynamic effects of flosequinan for congestive heart failure.
Haas GJ; Binkley PF; Carpenter JA; Leier CV
Am J Cardiol; 1989 Jun; 63(18):1354-9. PubMed ID: 2658526
[TBL] [Abstract][Full Text] [Related]
10. Hemodynamic and neurohormonal effects of flosequinan in patients with heart failure.
Isnard R; Lechat P; Pousset F; Carayon A; Kalotka H; Chikr H; Salloum J; Thomas D; Komajda M
Fundam Clin Pharmacol; 1997; 11(1):83-9. PubMed ID: 9182081
[TBL] [Abstract][Full Text] [Related]
11. Cardiocirculatory effects of afterload reduction with oral trimazosin in severe chronic congestive heart failure.
Awan NA; Hermanovich J; Whitcomb C; Skinner P; Mason DT
Am J Cardiol; 1979 Jul; 44(1):126-31. PubMed ID: 453037
[TBL] [Abstract][Full Text] [Related]
12. Duration and reproducibility of initial hemodynamic effects of flosequinan in patients with congestive heart failure.
Bartels GL; Remme WJ; Wiesfeld AC; Kok FJ; Look MP; Krauss XH; Kruyssen HA
Cardiovasc Drugs Ther; 1990 Jun; 4(3):705-12. PubMed ID: 2076381
[TBL] [Abstract][Full Text] [Related]
13. Effect of flosequinan in patients with acute-onset heart failure complicating acute myocardial infarction.
Schneeweiss A; Wynne RD; Marmor A
Crit Care Med; 1989 Sep; 17(9):879-81. PubMed ID: 2766758
[TBL] [Abstract][Full Text] [Related]
14. Acute and chronic effects of flosequinan on resting and exercise haemodynamics in congestive heart failure.
Thomas P; O'Gorman DJ; Sheridan DJ
Br J Clin Pharmacol; 1993 Dec; 36(6):539-46. PubMed ID: 12959270
[TBL] [Abstract][Full Text] [Related]
15. Alterations in left ventricular function, coronary hemodynamics and myocardial catecholamine balance with MDL 17043, a new inotropic vasodilator agent, in patients with severe heart failure.
Viquerat CE; Kereiakes D; Morris DL; Daly PA; Wexman M; Frank P; Parmley WW; Chatterjee K
J Am Coll Cardiol; 1985 Feb; 5(2 Pt 1):326-32. PubMed ID: 3155761
[TBL] [Abstract][Full Text] [Related]
16. Neurohormonal activation in severe heart failure: relations to patient death and the effect of treatment with flosequinan.
Moe GW; Rouleau JL; Charbonneau L; Proulx G; Arnold JM; Hall C; de Champlain J; Barr A; Sirois P; Packer M
Am Heart J; 2000 Apr; 139(4):587-95. PubMed ID: 10740139
[TBL] [Abstract][Full Text] [Related]
17. Flosequinan induces hemodynamic improvement in heart failure complicating acute myocardial infarction.
Schneeweiss A; Marmor A; Wynne RD
Herz; 1988 Aug; 13(4):259-62. PubMed ID: 3169679
[TBL] [Abstract][Full Text] [Related]
18. Hemodynamic and metabolic effects of isosorbide dinitrate in chronic congestive heart failure.
Gray R; Chatterjee K; Vyden JK; Ganz W; Forrester JS; Swan HJ
Am Heart J; 1975 Sep; 90(3):346-52. PubMed ID: 1163426
[TBL] [Abstract][Full Text] [Related]
19. Positive inotropy contributes to the hemodynamic mechanism of action of flosequinan (BTS 49465) in the intact dog.
Greenberg S; Touhey B
J Cardiovasc Pharmacol; 1990 Jun; 15(6):900-10. PubMed ID: 1694912
[TBL] [Abstract][Full Text] [Related]
20. Flosequinan: a vasodilator with positive inotropic activity.
Corin WJ; Monrad ES; Strom JA; Giustino S; Sonnenblick ES; LeJemtel T
Am Heart J; 1991 Feb; 121(2 Pt 1):537-40. PubMed ID: 1990760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
